View our range of modules specifically designed for healthcare professionals (HCPs), highlighting the pathophysiology and management of SCD.
These modules are accredited by the Continuing Professional Development (CPD) Certification Service and will each take approximately 45 minutes to complete.
Disease state and pathophysiology
A comprehensive overview of the disease state of SCD, including pathophysiology, complications and risks.
SCD management and treatment landscape
A training module covering the therapeutic landscape for SCD and its complications.
Crizanlizumab▼ – clinical data
An overview of the SUSTAIN study detailing the use of crizanlizumab in the prevention of recurrent vaso-occlusive crises (VOCs).
Indication: Crizanlizumab is indicated for the prevention of recurrent VOCs in patients with SCD who are aged 16 years and over. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.1
Crizanlizumab has a conditional marketing authorisation and further evidence is awaited.
Abbreviations: CPD, continuing professional development; HC, hydroxycarbamide; HCPs, healthcare professionals; HU, hydroxyurea; SCD, sickle cell disease; VOCs, vaso-occlusive crises.
- ADAKVEO® (crizanlizumab) Summary of Product Characteristics.
For more information, refer to the ADAKVEO® prescribing information available here:
Legal Category: POM
Marketing Authorisation (MA) number, quantities and price: EU/1/20/1476/001 £1,038.00 per 10ml vial